KODIAK SCIENCES INC. Debt Securities, Available-for-sale, Amortized Cost, Current
KODIAK SCIENCES INC. (KOD) had Debt Securities, Available-for-sale, Amortized Cost, Current of $104.67 million as of 2023-03-31, per its 10-Q filed 2023-05-15.
Discontinued › Notes › Debt Securities, Available-for-Sale, Amortized Cost
us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent · last filed 2024-03-28
- 2023-03-31: Debt Securities, Available-for-sale, Amortized Cost, Current $104.67M.
- 2022-12-31: Debt Securities, Available-for-sale, Amortized Cost, Current $289.81M.
- 2022-09-30: Debt Securities, Available-for-sale, Amortized Cost, Current $361.49M.
- 2022-06-30: Debt Securities, Available-for-sale, Amortized Cost, Current $427.05M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost, Current |
|---|---|
| 2023-03-31 | $104.67M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $289.81M 10-K · filed 2024-03-28 |
| 2022-09-30 | $361.49M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $427.05M 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |